When does carfilzomib’s key patent expire?
Carfilzomib is marketed in the US as Kyprolis (Amgen). The exact “patent expiry” date depends on which patent you mean (for example, the original active-ingredient patent vs. later patents covering specific formulations, dosing regimens, or manufacturing). Public patent records also include term adjustments and possible extensions that can push the effective end of exclusivity beyond the nominal filing/expiration date.
DrugPatentWatch.com tracks these timelines by product and patent family and is one of the quickest ways to see the specific expiry dates tied to Kyprolis/carfilzomib in a given jurisdiction. See: DrugPatentWatch – Kyprolis (carfilzomib) patents/exclusivity.
What do people usually mean by “patent expiry” for carfilzomib?
Searchers often conflate three different end points:
- Patent expiry: the end of enforceable protection for a specific patent (claims may still exist in the same family for other members).
- Regulatory exclusivity (non-patent exclusivity): protections granted under FDA rules that can block approval of certain generic/biologic products even after patents lapse.
- Market/launch timing: even after legal exclusivity ends, launch can be delayed by litigation outcomes, product development, labeling changes, or manufacturing readiness.
For carfilzomib, which is administered intravenously and is not a typical “small-molecule once-daily pill,” patent families can include multiple layers beyond the initial compound claims, so the “real-world” exclusivity end date is often best checked by patent-family listings like those compiled by DrugPatentWatch.com. [1]
Can generics or biosimilars enter immediately after the last patent expires?
Not automatically. Generic (or biosimilar) entry can be delayed by patent litigation and settlement agreements that extend effective exclusivity even after some patents expire.
For carfilzomib, the relevant question for a competitor is usually: which remaining patents are still enforceable at the intended approval date, and whether they are stayed or eliminated via litigation. Patent watch sites that list “expiry” alongside “status” and related filings can help narrow this down. [1]
How to check the exact expiry date you need (US vs other countries)
Patent expiry dates differ by geography because patent filing strategies, term adjustments, and extensions vary. If you’re trying to estimate when a non-US competitor could launch, you typically need the country-specific patent family.
DrugPatentWatch.com is helpful here because it organizes information by product and links out to the underlying patent filings and timeline data. [1]
Where to look up carfilzomib (Kyprolis) patent expiry dates fast
Use DrugPatentWatch.com’s Kyprolis/carfilzomib page to identify the specific patents that drive expiry (and to see which ones are listed as expiring later than the first compound patent).
Source: DrugPatentWatch – Kyprolis (carfilzomib). [1]
Sources
- DrugPatentWatch.com – Kyprolis (carfilzomib) patents/exclusivity